Scholarlink

Introduction <p>The development of automated robots for anticancer drug compounding is progressing, with anticipated improvements in operational efficiency. This study aimed to evaluate the potential of drug vial optimization (DVO) and the development multidose vials to safely and efficiently reduce medical costs through robotic compounding.</p> Methods <p>We conducted a survey of six anticancer drugs across four hospitals in Japan where robots are used.</p> Results <p>By implementing DVO, we estimated that the costs associated with wasted residual anticancer drug liquid could be reduced from ¥128.47 million [US$833,301, €787,293] (for original medicines equivalent) and ¥46.22 million [US$299,832, €283,278] (for generic medicines equivalent) to ¥30.75 million [US$199,460, €188,447] and ¥12.04 million [US$78,101, €73,789], respectively. This reduces waste costs by 75.8% for original medicine and 73.8% for generics. Furthermore, we estimated the potential preparation time savings associated with the development of multidose vials. A 5000-mg multidose vial of fluorouracil (5-FU) reduced the average robotic compounding time per day across the four hospitals by approximately 21&#xa0;minutes. Additional time savings included approximately 16&#xa0;minutes for a 260-mg paclitaxel vial, 13&#xa0;minutes for a 3000-mg gemcitabine vial, 11&#xa0;minutes for a 1000-mg bevacizumab vial, 6&#xa0;minutes for a 3000-mg oxaliplatin vial, and 2&#xa0;minutes for a 1200-mg rituximab vial. For 5-FU, which requires frequent preparation, there were days when the robotic compounding time was reduced by more than an hour.</p> Conclusions <p>The findings suggest that the development of multidose vials could improve operational efficiency and significantly reduce medical costs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficiently Reducing Medical Costs through Drug Vial Optimization and Multidose Vials for the Utilization of Cancer Drug Compounding Robots

  • 期刊论文

  • 发表日期：

    2025年2月1日

查看全文
  • Eiseki Usami,
  • Akihiro Moriya,
  • Taiga Jimichi,
  • Hiroki Asano,
  • Masayuki Miyazaki,
  • Masaki Hirabatake,
  • Nobuyuki Muroi,
  • Yuki Tonogai,
  • Yoko Hibi,
  • Michio Kimura

摘要

Introduction

The development of automated robots for anticancer drug compounding is progressing, with anticipated improvements in operational efficiency. This study aimed to evaluate the potential of drug vial optimization (DVO) and the development multidose vials to safely and efficiently reduce medical costs through robotic compounding.

Methods

We conducted a survey of six anticancer drugs across four hospitals in Japan where robots are used.

Results

By implementing DVO, we estimated that the costs associated with wasted residual anticancer drug liquid could be reduced from ¥128.47 million [US$833,301, €787,293] (for original medicines equivalent) and ¥46.22 million [US$299,832, €283,278] (for generic medicines equivalent) to ¥30.75 million [US$199,460, €188,447] and ¥12.04 million [US$78,101, €73,789], respectively. This reduces waste costs by 75.8% for original medicine and 73.8% for generics. Furthermore, we estimated the potential preparation time savings associated with the development of multidose vials. A 5000-mg multidose vial of fluorouracil (5-FU) reduced the average robotic compounding time per day across the four hospitals by approximately 21 minutes. Additional time savings included approximately 16 minutes for a 260-mg paclitaxel vial, 13 minutes for a 3000-mg gemcitabine vial, 11 minutes for a 1000-mg bevacizumab vial, 6 minutes for a 3000-mg oxaliplatin vial, and 2 minutes for a 1200-mg rituximab vial. For 5-FU, which requires frequent preparation, there were days when the robotic compounding time was reduced by more than an hour.

Conclusions

The findings suggest that the development of multidose vials could improve operational efficiency and significantly reduce medical costs.